Bone density in women with prolactinoma treated with dopamine agonists

Pituitary

Volumn 11, Issue 1, 2008, Pages 21-28

  Naliato, Erika Cesar de Oliveira ^a,b   Violante, Alice Helena Dutra ^a   Caldas, Dayse ^c   Farias, Maria Lucia Fleiuss ^a   Bussade, Isabela ^a   Lamounier Filho, Adilson ^a   Loureiro, Christiane Rezende ^a   Fontes, Rosita ^d   Schrank, Yolanda ^d   Loures, Thaissa ^a   Colao, Annamaria ^e  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Clementino Fraga Filho University Hospital ^*  (Brazil)

^c Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione   (Brazil)

^d Cardiovascular Magnetic Resonance and Computed Tomography Sector   (Brazil)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Bone density; Hyperprolactinemia; Prolactinoma; Women

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTRADIOL; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHORUS; PROLACTIN; TESTOSTERONE;

ADULT; AMENORRHEA; ARTICLE; BLOOD ANALYSIS; BODY MASS; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; OSTEOLYSIS; OSTEOPOROSIS; PREMENOPAUSE; PRIORITY JOURNAL; PROLACTINOMA;

ABSORPTIOMETRY, PHOTON; ADULT; AMENORRHEA; BIOLOGICAL MARKERS; BODY COMPOSITION; BONE DENSITY; BONE DISEASES, METABOLIC; BRAZIL; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DOPAMINE AGONISTS; ESTRADIOL; FEMALE; HUMANS; MULTIVARIATE ANALYSIS; PITUITARY NEOPLASMS; PREMENOPAUSE; PROLACTIN; PROLACTINOMA; RISK FACTORS; TREATMENT OUTCOME;

EID: 38649125602     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-007-0064-4     Document Type: Article

References (23)

1. Klibanski A, Biller BM, Rosenthal DI, Schoenfeld DA, Saxe V (1988) Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 67:124-130
2. Biller BM, Baum HB, Rosenthal DI, Saxe VC, Charpie PM, Klibanski A (1992) Progressive trabecular osteopenia in women with hyperprolactinemia amenorrhea. J Clin Endocrinol Metab 75:692-697
3. Kayath MJ, Lengyel AMJ, Vieira JGH (1993) Prevalence and magnitude of osteopenia in patients with prolactinoma. Braz J Med Biol Res 26:933-941
4. Di Somma C, Colao A, Di Sarno A, Klain M, Landi ML, Facciolli G, Pivonello R, Panza N, Salvatore M, Lombardi G (1998) Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 83:807-813
5. Colao A, Di Somma C, Loche S, Di Sarno A, Klain M, Pivonello R, Pietrosante M, Salvatore M, Lombardi G (2000) Prolactinomas in adolescents: Persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol 52:319-327
6. Naliato ECO, Farias MLF, Braucks GR, Costa FSR, Zylberberg D, Violante AHD (2005) Prevalence of osteopenia in men with prolactinoma. J Endocrinol Invest 28:12-17
7. Binkley N, Bilezikian JP, Kendler D, Leib E, Lewiecki E, Petak S (2006) Official positions of the international society for clinical densitometry and executive summary of the 2005 position development conference. J Clin Densitom 9:4-14
8. Schlechte J, El-Khoury G, Kathol M, Walkner L (1987) Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 64:1021-1026
9. Bonnick S (1998) Densitometric anatomy. Humana Press, Totowa, pp 31-64
10. Shaarawy M, El-Dawakhly A, Mosaad M, El-Sadek MM (1999) Biomarkers of bone turnover and bone mineral density in hyperprolactinemic amenorrheic women. Clin Chem Lab Med 37:433-438
11. Klibanski A, Greenspan S (1986) Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med 315:542-546
12. Schlechte J, Walkner L, Kathol M (1992) A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia. J Clin Endocrinol Metab 75:698-703
13. Hui SL, Perkins AJ, Zhou L, Longcope C, Econs MJ, Peacock M, McClintock C, Johnston CC Jr (2002) Bone loss at the femoral neck in premenopausal white women: Effects of weight change and sex-hormone levels. J Clin Endocrinol Metab 87:1539-1543
14. Roemmich JN, Clark PA, Mantzoros CS, Gurgol CM, Weltman A, Rogol AD (2003) Relationship of leptin to bone mineralization in children and adolescents. J Clin Endocrinol Metab 88:599-604
15. Blain H, Vuillemin A, Guillemin F, Durant R, Hanesse B, Talance N, Doucet B, Jeandel C (2002) Serum leptin level is a predictor of bone mineral density in postmenopausal women. J Clin Endocrinol Metab 87:1030-1035
16. Cincotta AH, Meier AH (1995) Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus). Metabolism 44:1349-1355
17. Kok P, Roelfsema F, Frölich M, Meinders AE, Pijl H (2004) Prolactin release is enhanced in proportion to excess visceral fat in obese women. J Clin Endocrinol Metab 89:4445-4449
18. Ciccarelli E, Savino L, Carlevatto V, Bertagna A, Isaia G, Camanni F (1988) Vertebral bone density in non-amenorrhoeic hyperprolactinemia. Clin Endocrinol 28:1-6
19. Khosla S, Melton J III, Atlinson EJ, O'Fallon W, Klee GG, Riggs L (1998) Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen. J Clin Endocrinol Metab 83:2266-2274
20. Manolagas S (2000) Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115-137
21. Compston J (2001) Sex steroids and bone. Physiol Rev 81:419-447
22. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 331:904-909
23. Caraceni MP, Corghi E, Ortolani S, Casazza S, D'Alberton A, Motta T (1985) Increased forearm bone mineral content after bromocriptine treatment in hyperprolactinemia. Calcif Tissue Int 37:687-689